Horizon Therapeutics Plc Overview
Horizon Therapeutics Plc (HZNP) has a ROE of 8.25%, below the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow8.25%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Horizon Therapeutics Plc (HZNP) currently reports a ROE of 8.25%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Horizon Therapeutics Plc's ROE history and peer comparisons.
Horizon Therapeutics Plc's ROE of 8.25% is lower than the Healthcare sector average of 20.86%. That is roughly 60.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Horizon Therapeutics Plc's current 8.25% should be judged against Healthcare norms (sector average: 20.86%) and against HZNP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 8.25%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Horizon Therapeutics Plc, and consider following HZNP for alerts when major investors trade the stock.
Horizon Therapeutics Plc is classified in the Healthcare sector. On ROE, it currently shows 8.25% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HZNP with unrelated industries.
